History did not repeat itself for cannabinoid developer Zynerba Pharmaceuticals Inc. A month after shares (NASDAQ:ZYNE) of the Devon, Pa.-based company lost more than half their value following a primary endpoint miss in the phase II study of lead candidate cannabidiol (CBD) gel ZYN-002, which failed to reduce focal seizures in adults with epilepsy, Zynerba rebounded in a big way with top-line findings from the open-label exploratory phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial evaluating the same agent in pediatric and adolescent patients with fragile X syndrome (FXS).